Kronos Bio, Inc.

Equities

KRON

US50107A1043

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 15/05/2024 am IST			5-day change	1st Jan Change
0.9995 ^USD	-2.01%		-4.81%	-20.04%

09/05	Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $2.52M	MT
09/05	Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Kronos Bio, Inc. Appoints Roger Dansey as Member of the Nominating and Corporate Governance Committee of the Board

May 31, 2023 at 02:06 am IST

On April 7, 2023, Kronos Bio, Inc. appointed Roger Dansey, M.D to Board of Directors (the “Board”) as a Class I director with a term ending at annual meeting of stockholders to be held in 2024. On May 26, 2023, Dr. Dansey was appointed as a member of the Nominating and Corporate Governance Committee of the Board.

Latest news about Kronos Bio, Inc.

Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $2.52M	10/05	MT
Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M	21/03	MT
Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03	CI
Kronos Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Kronos Bio, Inc. Announces to Assess KB-0742 At Planned New Dose Schedule in Ongoing Phase 1/2 Study	08/03	CI
Kronos Bio Plans to Reduction in Force	08/03	CI
Kronos Bio Announces Management Shakeup, 3 Top Managers to Step Down in February	26/01	MT
Kronos Bio, Inc. Announces Executive Changes	25/01	CI
Investors got more clues that rate cuts are imminent	19/12
Piper Sandler Trims Price Target on Kronos Bio to $6 From $7, Keeps Overweight Rating	19/12	MT
HC Wainwright Adjusts Price Target on Kronos Bio to $2.50 From $9, Keeps Buy Rating	19/12	MT
Kronos Bio, Inc. Announces Pipeline Update and p300 KAT Inhibitor Development Candidate	19/12	CI
Kronos Bio Insider Bought Shares Worth $1,470,395, According to a Recent SEC Filing	18/11	MT
Earnings Flash (KRON) KRONOS BIO Reports Q3 Revenue $917,000	14/11	MT
Kronos Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Kronos Bio to Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 Kb-0742 Study At the Connective Tissue Oncology Society Annual Meeting	27/23/27	CI
Transcript : Kronos Bio, Inc. - Special Call	14/23/14
Kronos Bio, Inc. Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study At AACR-NCI-EORTC	13/23/13	CI
Kronos Bio Appoints Sandra Gardiner as Interim Chief Financial Officer	18/23/18	MT
Kronos Bio, Inc. Appoints Sandra A. Gardiner as Interim Chief Financial Officer	18/23/18	CI
Kronos Bio, Inc. Appoints Sandra A. Gardiner as Principal Financial Officer and Principal Accounting Officer	18/23/18	CI
HC Wainwright Adjusts Price Target on Kronos Bio to $9 From $10, Maintains Buy Rating	21/23/21	MT
Kronos Bio Finance Chief Yasir Al-Wakeel Resigning	17/23/17	MT
Kronos Bio Announces Resignation of Yasir Al-Wakeel as Head of Corporate Development, Effective from September 15, 2023	17/23/17	CI

Chart Kronos Bio, Inc.

Duration

Period

More charts

Company Profile

Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.

Sector

Biotechnology & Medical Research

Calendar

01/06/2024 - American Society of Clinical Oncology Annual Meeting - Abstract No:3102

More about the company

Income Statement Evolution

More financial data

Ratings for Kronos Bio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.02 USD

Average target price

4.125 USD

Spread / Average Target

+304.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KRONOS BIO, INC.	-20.04%	6.13Cr
MODERNA, INC.	+29.03%	4.82TCr
IQVIA HOLDINGS INC.	-0.10%	4.17TCr
LONZA GROUP AG	+43.45%	4.1TCr
CELLTRION, INC.	-5.26%	2.88TCr
ICON PUBLIC LIMITED COMPANY	+11.48%	2.56TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	1.9TCr
BIO-TECHNE CORPORATION	+9.06%	1.29TCr
MEDPACE HOLDINGS, INC.	+30.01%	1.2TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	1.18TCr

Other Biotechnology & Medical Research